2. Search Result
Search Result
Results for "

autophagy+activator

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

3

Fluorescent Dyes

3

Biochemical Assay Reagents

7

Natural
Products

3

Isotope-Labeled Compounds

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10219
    Rapamycin
    Maximum Cited Publications
    1338 Publications Verification

    Sirolimus; AY-22989; NSC 226080

    		 mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-13259
    MG-132
    Maximum Cited Publications
    1998 Publications Verification

    Z-Leu-Leu-Leu-al; MG132

    		 Proteasome Autophagy Apoptosis Cancer
    MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis .
    MG-132
  • HY-70002
    Enzalutamide
    210+ Cited Publications

    MDV3100

    		 Androgen Receptor Autophagy Cancer
    Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .
    Enzalutamide
  • HY-13418A
    Dorsomorphin
    750+ Cited Publications

    Compound C; BML-275

    		 Organoid AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599) .
    Dorsomorphin
  • HY-13418
    Dorsomorphin dihydrochloride
    750+ Cited Publications

    Compound C dihydrochloride; BML-275 dihydrochloride

    		 Organoid AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
    Dorsomorphin dihydrochloride
  • HY-B1232
    Metyrapone
    10+ Cited Publications

    Su-4885

    		 Endogenous Metabolite Cytochrome P450 Autophagy Neurological Disease Metabolic Disease Endocrinology Cancer
    Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .
    Metyrapone
  • HY-128892
    EN6
    5 Publications Verification

    		 Autophagy Neurological Disease
    EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
    EN6
  • HY-10249
    GSK-690693
    40+ Cited Publications

    		 Akt AMPK Autophagy Cancer
    GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation .
    GSK-690693
  • HY-70002R
    Enzalutamide (Standard)

    MDV3100 (Standard)

    		 Reference Standards Androgen Receptor Autophagy Cancer
    Enzalutamide (Standard) is the analytical standard of Enzalutamide. This product is intended for research and analytical applications. Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator .
    Enzalutamide (Standard)
  • HY-N0914
    Ajugol
    3 Publications Verification

    		 Parasite Autophagy Interleukin Related Reactive Oxygen Species (ROS) mTOR Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Ajugol is an orally active iridoid glycoside found in the traditional Chinese medicine Leonurus japonicus. Ajugol is an autophagy activator. Ajugol activates TFEB-mediated autophagy and lysosomal biogenesis. Ajugol also has anti-inflammatory effects. Ajugol has great potential in the research of asthma, non-alcoholic fatty liver disease (NAFLD), and osteoarthritis .
    Ajugol
  • HY-10219S
    Rapamycin-d3
    1 Publications Verification

    Sirolimus-d3; AY-22989-d3; NSC 226080-d3

    		 Isotope-Labeled Compounds mTOR FKBP Autophagy Cancer
    Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-d3
  • HY-10219R
    Rapamycin (Standard)

    Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)

    		 Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (Standard)
  • HY-12034
    WYE-354
    5+ Cited Publications

    		 mTOR Autophagy Apoptosis Cancer
    WYE-354 is an ATP-competitive mTOR inhibitor with an IC50 of 5 nM. WYE-354 also inhibits PI3Kα and PI3Kγ with IC50s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both mTORC1 and mTORC2. WYE-354 induces autophagy activation in vitro .
    WYE-354
  • HY-10219S1
    Rapamycin-13C,d3

    Sirolimus-13C,d3; AY-22989-13C,d3 NSC 226080-13C,d3

    		 Isotope-Labeled Compounds mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin- 13C,d3 (Sirolimus- 13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3
  • HY-10219G
    Rapamycin

    Sirolimus; AY-22989; NSC 226080

    		 mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Infection Cancer
    Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-10219GL
    Rapamycin (GMP Like)

    Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

    		 mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (GMP Like)
  • HY-162866
    CXM102

    		Autophagy Metabolic Disease
    CXM102 is an autophagy activator. CXM102 can induce autophagy in aged BMSCs, leading to the rejuvenation of BMSCs and preferential differentiation into osteoblasts. CXM102 promotes the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. CXM102 can stimulate bone synthesis metabolism in middle-aged male mice, reduce bone marrow adipocytes, delay bone loss, lower serum inflammation levels, decrease organ fibrosis, and extend the lifespan of the mice .
    CXM102
  • HY-170667
    Autophagy activator-1

    		Autophagy HSP Cancer
    Autophagy activator-1 (Compound B2) is an autophagy activator Autophagy. Activator-1 ultimately leads to the activation of autophagy by downregulating key members of the HSP70 family and activating the unfolded protein response .
    Autophagy activator-1
  • HY-13259G
    MG-132

    Z-Leu-Leu-Leu-al

    		 Proteasome Autophagy Apoptosis Cancer
    MG-132 (GMP) (Z-Leu-Leu-Leu-al (GMP)) is MG-132 (HY-13259) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis .
    MG-132
  • HY-174157
    AR493

    		Autophagy AMPK Neurological Disease Metabolic Disease
    AR493 is an autophagy activator acting on AMPK (adenosine monophosphate-activated protein kinase). AR493 regulates pathways related to cellular energy sensing and increases autophagy levels. AR493 is promising for research of aging-associated diseases (such as diabetes, neurodegenerative diseases) and autophagy regulation .
    AR493
  • HY-182938
    Autophagy activator-2

    		Autophagy Metabolic Disease
    Autophagy activator-2 is a potent autophagy activator with EC50 values of 14.33 μM. Autophagy activator-2 acts as a proteostasis modulator and small-molecule chaperone that upregulates I1061T mutant NPC1 expression and facilitates cholesterol efflux. Autophagy activator-2 reduces lysosomal hydrolase levels. Autophagy activator-2 can be used for the study of Niemann-Pick Type C disease .
    Autophagy activator-2
  • HY-168507
    SG31

    		Autophagy Cancer
    SG31 is a potent autophagy activator via the AMPK/ULK1-dependent pathway .
    SG31
  • HY-13418R
    Dorsomorphin dihydrochloride (Standard)

    Compound C dihydrochloride (Standard); BML-275 dihydrochloride (Standard)

    		 Organoid AMPK TGF-β Receptor Autophagy Reference Standards Cancer
    Dorsomorphin (dihydrochloride) (Standard) is the analytical standard of Dorsomorphin (dihydrochloride). This product is intended for research and analytical applications. Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
    Dorsomorphin dihydrochloride (Standard)
  • HY-N0914R
    Ajugol (Standard)

    		Reference Standards Parasite Autophagy Interleukin Related Reactive Oxygen Species (ROS) mTOR Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Ajugol (Standard) is the analytical standard of Ajugol (HY-N0914). This product is intended for research and analytical applications. Ajugol is an orally active iridoid glycoside found in the traditional Chinese medicine Leonurus japonicus. Ajugol is an autophagy activator. Ajugol activates TFEB-mediated autophagy and lysosomal biogenesis. Ajugol also has anti-inflammatory effects. Ajugol has great potential in the research of asthma, non-alcoholic fatty liver disease (NAFLD), and osteoarthritis .
    Ajugol (Standard)
  • HY-W765245
    Rapamycin-13C,d3-1

    Sirolimus-13C,d3-1; AY-22989-13C,d3-1

    		 Isotope-Labeled Compounds Fungal mTOR Bacterial Autophagy Endogenous Metabolite FKBP Antibiotic Cancer
    Rapamycin- 13C,d3-1 (Sirolimus- 13C,d3-1) is the deuterium labeled and 13C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3-1
  • HY-B1232A
    Metyrapone Tartrate

    Su-4885 Tartrate

    		 Endogenous Metabolite Cytochrome P450 Autophagy mTOR Neurological Disease Endocrinology
    Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression .
    Metyrapone Tartrate
  • HY-B1232R
    Metyrapone (Standard)

    Su-4885 (Standard)

    		 Reference Standards Endogenous Metabolite Cytochrome P450 Autophagy Neurological Disease Metabolic Disease Endocrinology Cancer
    Metyrapone (Standard) is the analytical standard of Metyrapone. This product is intended for research and analytical applications. Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression .
    Metyrapone (Standard)
  • HY-181724
    501A054

    		Autophagy Cancer
    501A054 is an autophagy activator. 501A054 induces autophagy-dependent cell death via autophagy activation. 501A054 can be used in studies on autophagy regulation such as cervical cancer .
    501A054
  • HY-E70875
    ULK1 Recombinant Human Active Protein Kinase

    		ULK Cancer
    ULK1 (unc-51 like autophagy activating kinase 1), one of the core human autophagy-related genes, encodes a serine-threonine kinase and the mammalian ortholog of the yeast ATG1 gene. ULK1 Recombinant Human Active Protein Kinase is a recombinant ULK1 protein that can be used to study ULK1-related functions .
    ULK1 Recombinant Human Active Protein Kinase
  • HY-10249R
    GSK-690693 (Standard)

    		Reference Standards Akt AMPK Autophagy Cancer
    GSK-690693 (Standard) is the analytical standard of GSK-690693 (HY-10249). This product is intended for research and analytical applications. GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation .
    GSK-690693 (Standard)
  • HY-180119
    IKKβ-IN-5

    		IKK NF-κB Autophagy Cancer
    IKKβ-IN-5 is an orally active and selective IKKβ inhibitor with an IC50 of 7.5 nM. IKKβ-IN-5 directly inhibits IKKβ phosphorylation and attenuates NF κB mediated inflammatory and survival signals while promoting autophagy flux. IKKβ-IN-5 exhibits a 6-fold selectivity forIKKβ over the homologous kinase IKKα. IKKβ-IN-5 exerts robust antiproliferative effects through a dual mechanism involving G₂/M phase cell cycle arrest and autophagy activation, even under inflammatory stimulation in vitro. IKKβ-IN-5 demonstrates favorable pharmacokinetics and suppresses tumor growth in vivo. IKKβ-IN-5 can be used for colorectal cancer and potentially other inflammation driven malignancies research .
    IKKβ-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: